Rapid Benzodiazepine Detoxification Using Flumazenil - 1

The purpose of this study is to verify the hypothesis that the benzodiazepine antagonist, flumazenil, will reduce acute benzodiazepine withdrawal.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Substance-related Disorders Chemically-Induced Disorders Mental Disorders

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Yale University, Psychiatry

New Haven, Connecticut, 06519, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Please contact site for information.

Treatment and study plan

Flumazenil

Drug

Primary outcomes

Benzodiazepine withdrawal severity

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

National Institute on Drug Abuse (NIDA)

Registry information

Official study title

Rapid Benzodiazepine Detoxification Using Flumazenil

Important dates

Study start: 1993
Primary completion: 1994
Study completion: 1994
First posted: Sep 21, 1999
Registry last updated: Sep 8, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed